
- Pharmaceutical Executive-04-01-2002
South Africa Continues to Resist Anti-AIDs Efforts
Capetown-In March, ruling on a case initiated by the Treatment Action Campaign, Save Our Babies, and the Children's Rights Centre, Judge Chris Botha ordered the South African government to provide the anti-retroviral nevirapine to all HIV-positive pregnant women.
Capetown-In March, ruling on a case initiated by the Treatment Action Campaign, Save Our Babies, and the Children's Rights Centre, Judge Chris Botha ordered the South African government to provide the anti-retroviral nevirapine to all HIV-positive pregnant women.
Although Botha gave the government the right to appeal his decision, he mandated that the medicines be kept available while any appeal is pending. Considering it unlikely that his decision would be reversed, he said it would save some lives even if it was overturned on appeal.
Health ministry spokesman Sibani Mngadi said the government would consider whether to appeal after the African National Congress discussed it at a national executive meeting. The ANC chastised former US president Jimmy Carter for telling the South African government that it could learn much from the AIDS policies of African countries that were smaller and poorer than its own. An ANC spokesman accused Carter of urging the country to treat its people as guinea pigs to further the interests of the pharmaceutical industry.
Articles in this issue
over 23 years ago
PhRMA Focuses on Formularies and Coverageover 23 years ago
Drug Promotion to Docs on the Defensiveover 23 years ago
GSK Faces Bribe Charges, Changing of the Guardover 23 years ago
HBA's 2002 Woman of the Year Leads Transformationover 23 years ago
Risks and Rewards for Pharma in Post-WTO Chinaover 23 years ago
New FDA Leader Has Full Agendaover 23 years ago
What Women Wantover 23 years ago
Medicare Card Competition Heats Upover 23 years ago
MSF Exposes Malaria Mythsover 23 years ago
Speechless in New YorkNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.





